News and Trends 18 Aug 2022 CSL gets positive results for preventive treatment in patients with hereditary angioedema Hereditary angioedema (HAE), a condition that causes recurrent attacks of severe swelling, could be prevented by a monoclonal antibody after positive top line phase 3 results were reported. Garadacimab, biotech… August 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2017 Next-Gen Drug Conjugates Bank €46M in Series B with American Investors …the drug behaves like an antibody-drug conjugate with an engineered bicyclic peptide instead of an antibody. BT1718’s small size of 1.5 to 2 kDa allows it to enter a solid… June 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 SOTIO exercises option on ADC program SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB) for antibody-drug conjugate (ADC) SOT106, which… November 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 4 Oct 2017 4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was… October 4, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2018 Update: Yet Another ADC Company Makes Bank, This Time in Series B …Basel-based biotech making its debut as a player in antibody drug conjugates (ADCs). It just raised 20M CHF in Series B, with PPF leading the way. With the funds, NBE… June 29, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 Mablink Bioscience receives €31M series A funding for ADC pipeline French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody… October 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2017 Novartis Relies on Biotech to keep up its Solid Financial Performance …The company also has ongoing partnerships with biotechs such as the German Morphosys. Together, the team is currently evaluating 12 therapeutic antibody candidates for applications ranging from obesity and type… January 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Feb 2024 Japan’s ten hottest biotech companies in healthcare …regenerative route to saving the heart via stem cell therapy. The same month the company announced its collaboration with Novo Nordisk to develop its lead candidate, HS-001. In the lab,… February 27, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 18 Nov 2022 How cardioids can usher in the next generation of drug discovery …approaches use animal models and cell-based screening assays to select new drug candidates. You first start with a large number of drug candidates that are narrowed down to the best… November 18, 2022 - 6 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Mar 2023 5 hearing loss biotech companies you should know about …pathophysiology and etiology of diseases related to hearing loss, allowing it to select the best targets and mechanisms of action for drug candidates. SENS-401 is Sensorion’s clinical-stage small molecule drug… March 29, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 1 Nov 2024 Can AI cure Alzheimer’s disease? …AI platform, Centaur Chemist, uses predictive modeling to streamline the selection of candidate compounds. This platform has already brought three AI-designed drug candidates to clinical testing, including DSP-0038 for Alzheimer’s… November 1, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 20 Nov 2024 Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024 …alike. U.S.-based MBX’s $187.7 million offering will fund its lead candidate MBX 2109 – hoping to take on Yorvipath – into phase 3 studies. The IPO was following the news… November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email